Acute Myeloid Leukemia

Rydapt approved for adults with acute myeloid leukemia

(HealthDay)—Rydapt (midostaurin) has been approved by the U.S. Food and Drug Administration, in combination with chemotherapy, to treat adults with acute myeloid leukemia (AML) who have a specific genetic mutation dubbed ...

Apr 28, 2017
popularity0 comments 0

Team uncovers novel epigenetic changes in leukemia

UT Health San Antonio researchers discovered epigenetic changes that contribute to one-fifth of cases of acute myeloid leukemia (AML), an aggressive cancer that arises out of the blood-forming cells in bone marrow.

May 10, 2017
popularity16 comments 0

New inhibitor drug shows promise in relapsed leukemia

A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers at the Perelman School of Medicine at the University of Pennsylvania ...

Jun 21, 2017
popularity0 comments 0

Mysterious gene transcripts after cancer therapy

Tumor suppressor genes protect cells from malignant transformation. If they are turned off as a result of chemical modifications in DNA, called epigenetic labels, this contributes to the development of cancer. As opposed ...

Jun 12, 2017
popularity116 comments 0

Protein network signals found to drive myeloid leukemias

Researchers have uncovered how mutations in a protein network drive several high-risk leukemias, offering new prospects for novel therapies. An existing drug might be repurposed to treat these leukemias, and the new understanding ...

Jun 14, 2017
popularity0 comments 0

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

A large-scale 'germ trap' solution for hospitals

When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Cognitive cross-training enhances learning, study finds

Just as athletes cross-train to improve physical skills, those wanting to enhance cognitive skills can benefit from multiple ways of exercising the brain, according to a comprehensive new study from University of Illinois ...

Lutein may counter cognitive aging, study finds

Spinach and kale are favorites of those looking to stay physically fit, but they also could keep consumers cognitively fit, according to a new study from University of Illinois researchers.